Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast for pulmonary vascular resistance in COPD-sleep apnea overlap syndrome
2012-003037-41Phase 2Terminated
- Sponsor
- Medical University of Graz
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of roflumilast in pulmonary hypertension (PH), chronic obstructive pulmonary disease (COPD) and sleep apnea (2 arms), sponsored by Medical University of Graz. Primary endpoint: Change in pulmonary vascular resistance. Started Aug 2012; status: terminated.
02
Drugs
roflumilast
03
Conditions
pulmonary hypertension (PH)chronic obstructive pulmonary disease (COPD)sleep apnea
Beyond the preview
Go deeper on 2012-003037-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003037-41.